Linking preclinical mechanisms of neurodegeneration to individual risk profiles of Alzheimer's disease

将神经退行性变的临床前机制与阿尔茨海默病的个体风险状况联系起来

• 批准号: 435889
• 负责人: Schmitz Taylor W
• 金额: $ 76.07万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-10-01 至 2025-10-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=435889&lang=en
• 关键词: Alzheimer'S Disease; Basal Forebrain Cholinergic System; Humans; Longitudinal Design; Mouse Models; Neurodegeneration; Positron Emission Tomography; Preclinical Biomarkers; Structural Magnetic Resonance Imaging; Translational

Alzheimer's disease (AD) is one of the largest impending healthcare policy crises worldwide. An estimated 564,000 Canadians currently live with dementia. By 2031, this figure will increase by 66%. For many diseases with age as a primary risk factor, such

阿尔茨海默病（AD）是全球最大的医疗保健政策危机之一。据估计，目前有56.4万加拿大人患有痴呆症。到2031年，这一数字将增加66%。对于许多以年龄为主要风险因素的疾病，